Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: Where we stand

Expert Review of Anticancer Therapy

Volumn 9, Issue 3, 2009, Pages 357-363

  Visani, Giuseppe ^a   Isidori, Alessandro ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Anthracycline; B cell non Hodgkin's lymphoma; Cardiotoxicity; Efficacy; Nonpegylated liposomal doxorubicin; Safety

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CAELIX; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN B; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER RELAPSE; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPTIMAL DRUG DOSE; PERIPHERAL NEUROPATHY; REVIEW; SEPSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; LIPOSOMES; LYMPHOMA, AIDS-RELATED; LYMPHOMA, B-CELL; MIDDLE AGED; PREDNISOLONE; VINCRISTINE;

EID: 65749095528     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.3.357     Document Type: Review

References (31)

1. Armitage JO, Fyfe MAE, Lewis J et al. Long term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J. Clin. Oncol. 2, 898-902 (1984).
2. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328(14), 1002-1006 (1993).
3. Gordon LI, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non- Hodgkin's lymphoma. N. Engl. J. Med. 327(19), 1342-1349 (1992).
4. Jerkeman M, Anderson H, Cavallin-Ståhl E et al. CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Ann. Oncol. 10, 1079-1086 (1999).
5. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
6. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7, 379-391 (2006).
7. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin. Oncol. 33(3 Suppl. 8), S2-S7 (2006).
8. Johnson SA. Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin. Oncol. 33(3 Suppl. 8), S22-S27 (2006).
9. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 26(22), 3777-3784 (2008).
10. Conley BA, Egorin MJ, Whitacre MT et al. Phase I and pharmacokinetic trial of liposome encapsulated doxorubicin. Cancer Chemother. Pharmacol. 33, 107-112 (1993).
11. Cowens JW, Creaven PJ, Greco WR et al. Initial clinical (Phase I) trial of Myocet (doxorubicin encapsulated in liposomes). Cancer Res. 53, 2796-2802 (1993).
12. Ostro MJ. Liposomes: from the bench to the marketplace - doxorubicin as an example. In: Liposomes in the Therapy of Infectious Diseases and Cancer. Fidler IJ, Lopez-Berestein G (Eds). Alan Liss, Inc., NY, USA 155-163 (1989).
13. Mayer LD, Bally MB, Cullis PR et al. Comparison of free and liposomeencapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 53, 183-190 (1990).
14. Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposomeencapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19, 1444-1454 (2001).
15. Valero V, Buzdar AU, Theriault RL et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluoracil as first-line therapy in patients with metastatic breast cancer. J. Clin. Oncol. 17, 1425-1434 (1999).
16. Mrozek E, Rhoades CA, Allen J, Hade EM, Shapiro CL. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients. Ann. Oncol. 16, 1087-1093 (2005).
17. Schmid P, Krocker J, Jehn C et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a Phase II trial. Ann. Oncol. 16, 1624-1631 (2005).
18. Harris L, Batist G, Belt R et al. Liposomeencapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94, 25-36 (2002).
19. Chan S, Davidson N, Juozaityte E et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as firstline therapy for metastatic breast cancer. Ann. Oncol. 15, 1527-1534 (2004).
20. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-Cancer Drugs 17, 587-594 (2006).
21. Levine AM, Tulpule A, Espina B et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J. Clin. Oncol. 22(13), 2662-2670 (2004).
22. Tulpule A, Sherrod A, Dharmapala D et al. Multidrug resistance (MDR-1) expression in AIDS related lymphomas. Leuk. Res. 26, 121-127 (2002).
23. Rahman A, Husain SR, Siddiqui J et al. Liposome mediated modulation of multidrug resistance in human HL-60 leukemia cells. J. Natl Cancer Inst. 84, 1909-1915 (1992).
24. Thierry AR, Vige D, Coughlin SS et al. Modulation of doxorubicin resistance in multidrug resistant cells by liposomes. FASEB J. 7, 572-579 (1993).
25. Tulpule A, Espina BM, Berman N et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin. Lymphoma Myeloma 7(1), 59-64 (2006).
26. Rigacci L, Mappa S, Nassi L et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol. Oncol. 25(4), 198-203 (2007).
27. Visani G, Ferrara F, Alesiani F et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk. Lymphoma 49(6), 1081-1086 (2008).
28. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 5(3), 224-237 (2000)
29. Herrero J, Gomez-Codina J, Provencio M et al. First efficacy assessment of a Phase II study with cyclophosphamide, vincristine, liposomal doxorubicin, and prednisone plus rituximab, administered every two weeks (R-COMP-14) as primary treatment for NHL. J. Clin. Oncol. 25(Suppl. 18) (2007) (ASCO Meeting Abstracts 18519).
30. Iannitto E, Luminari S, Mammi C et al. Non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) as initial treatment for patients with splenic marginal zone lymphoma (SMZL). A GISL study. Blood 110(11), A1293 (2007).
31. Dando TM, Keating GM. Liposomal doxorubicin: a review of its use in metastatic breast cancer and potential in non-Hodgkin lymphoma. Am. J. Cancer 4(3), 193-206 (2005).